Overview

Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma

Status:
Active, not recruiting

Trial end date:
2034-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide pre-treatment.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Takara Bio Inc.

Treatments:

Cyclophosphamide